GE Healthcare announced Oct. 5 a definitive agreement to acquire SOFIE Biosciences, a Positron Emission Tomography radiopharmaceutical company, for $945 million in cash.
SOFIE Biosciences manufactures PET radiopharmaceuticals including Flyrcado (flurpiridaz F18 injection), which the FDA approved in 2024 to detect myocardial ischemia and infarction. Trilantic North America currently owns SOFIE.
GE Healthcare and Trilantic North America expect the deal to close in the first half of 2027, pending regulatory approval and other closing conditions.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
